Epidermal growth factor receptor (EGFR) mutations, a common oncogenic driver in non-small-cell lung cancer (NSCLC), can be targeted by EGFR tyrosine kinase inhibitors (TKIs) to improve patient prognosis. Here, EGFR is linked to non-small cell lung carcinoma.